2. World Health Organization. WHO Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents [Internet]. Geneva: World Health Organization. 2018 [cited 2021 Dec 27]. Available from:
https://www.who.int/publications/i/item/9789241550390.
4. Nury E, Schmucker C, Nagavci B, Motschall E, Nitschke K, Schulte E, Wegwarth O, Meerpohl JJ. Efficacy and safety of strong opioids for chronic non-cancer pain and chronic low back pain: a systematic review and meta-analyses. Pain 2021;Jul. 28. [Epub].
https://doi.org/10.1097/j.pain.0000000000002423
5. Cleary J, Radbruch L, Torode J, Cherny NI. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Asia: a report from the Global Opioid Policy Initiative (GOPI). Ann Oncol 2013;24 Suppl 11:xi24-x32.
6. Korea Institute of Drug Safety and RIsk Management. Big data analysis service for opioid medicines [Internet]. Anyang: Korea Institute of Drug Safety and RIsk Management. 2021 [cited 2021 Dec 1]. Available from:
https://data.nims.or.kr/main.do
7. Health Insurance Review and Assessment Service. The assessment for prescription pattern of opioid analgesics in Korean patients with chronic non-cancer pain [Internet]. Wonju: Health Insurance Review and Assessment Service. 2018 [cited 2021 Nov 28]. Available from:
https://repository.hira.or.kr/handle/2019.oak/1461
8. Salz T, Mishra A, Gennarelli RL, Lipitz-Snyderman A, Moryl N, Tringale KR, Boudreau DM, Kriplani A, Jinna S, Korenstein D. Safety of opioid prescribing among older cancer survivors. Cancer 2021;Oct. 11. [Epub].
https://doi.org/10.1002/cncr.33963
10. Go SI, Kim JH, Lee GW, Kang JH. Successful treatment with transdermal buprenorphine patch in opioid-dependent cancer patients: case series. Korean J Hosp Palliat Care 2018;21:152-157.
12. Park SS, Baik MS. A qualitative study on the hidden crime rate measurement of drug crimes. Korean Police Stud Rev 2019;18:151-170.
15. Kalso E. Oxycodone. J Pain Symptom Manage 2005;29((5 Suppl):S47-S56.
16. Murray A, Hagen NA. Hydromorphone. J Pain Symptom Manage 2005;29((5 Suppl):S57-S66.
17. Stanley TH. The fentanyl story. J Pain 2014;15:1215-1226.
19. Pert CB, Snyder SH. Opiate receptor: demonstration in nervous tissue. Science 1973;179:1011-1014.
20. Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 1975;258:577-580.
21. Burns DL, Hewlett EL, Moss J, Vaughan M. Pertussis toxin inhibits enkephalin stimulation of GTPase of NG108-15 cells. J Biol Chem 1983;258:1435-1438.
26. Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA 1995;274:1870-1873.
27. Bandieri E, Romero M, Ripamonti CI, Artioli F, Sichetti D, Fanizza C, Santini D, Cavanna L, Melotti B, Conte PF, Roila F, Cascinu S, Bruera E, Tognoni G, Luppi M; Early Strong Opioid Treatment Study (ESOT) Investigators. Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain. J Clin Oncol 2016;34:436-442.
28. Hadley G, Derry S, Moore RA, Wiffen PJ. Transdermal fentanyl for cancer pain. Cochrane Database Syst Rev 2013;(10):CD010270.
29. Yu S, Shen W, Yu L, Hou Y, Han J, Richards HM. Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlledrelease in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. J Pain 2014;15:835-844.
30. Schmidt-Hansen M, Bennett MI, Arnold S, Bromham N, Hilgart JS. Oxycodone for cancer-related pain. Cochrane Database Syst Rev 2017;(8):CD003870.
31. Reddy A, Yennurajalingam S, Pulivarthi K, Palla SL, Wang X, Kwon JH, Frisbee-Hume S, Bruera E. Frequency, outcome, and predictors of success within 6 weeks of an opioid rotation among outpatients with cancer receiving strong opioids. Oncologist 2013;18:212-220.
32. Davies A, Buchanan A, Zeppetella G, Porta-Sales J, Likar R, Weismayr W, Slama O, Korhonen T, Filbet M, Poulain P, Mystakidou K, Ardavanis A, O’Brien T, Wilkinson P, Caraceni A, Zucco F, Zuurmond W, Andersen S, Damkier A, Vejlgaard T, Nauck F, Radbruch L, Sjolund KF, Stenberg M. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage 2013;46:619-628.
33. Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths - United States, 2010-2015. MMWR Morb Mortal Wkly Rep 2016;65:1445-1452.
34. Leung PTM, Macdonald EM, Stanbrook MB, Dhalla IA, Juurlink DN. A 1980 letter on the risk of opioid addiction. N Engl J Med 2017;376:2194-2195.
35. Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain 2015;156:569-576.
37. Rehni AK, Jaggi AS, Singh N. Opioid withdrawal syndrome: emerging concepts and novel therapeutic targets. CNS Neurol Disord Drug Targets 2013;12:112-125.
38. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D; Buprenorphine/Naloxone Collaborative Study Group. Officebased treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003;349:949-958.
39. Imam MZ, Kuo A, Ghassabian S, Smith MT. Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression. Neuropharmacology 2018;131:238-255.
40. Kon R, Ikarashi N, Hayakawa A, Haga Y, Fueki A, Kusunoki Y, Tajima M, Ochiai W, Machida Y, Sugiyama K. Morphineinduced constipation develops with increased aquaporin-3 expression in the colon via increased serotonin secretion. Toxicol Sci 2015;145:337-347.
42. Burness CB, Keating GM. Oxycodone/Naloxone prolongedrelease: a review of its use in the management of chronic pain while counteracting opioid-induced constipation. Drugs 2014;74:353-375.
44. Lehnen N, Heuser F, Saglam M, Schulz CM, Wagner KJ, Taki M, Kochs EF, Jahn K, Brandt T, Glasauer S, Schneider E. Opioid-induced nausea involves a vestibular problem preventable by head-rest. PLoS One 2015;10:e0135263.
45. Kamei J, Ohsawa M, Hayashi SS, Nakanishi Y. Effect of chronic pain on morphine-induced respiratory depression in mice. Neuroscience 2011;174:224-233.
46. Hill R, Santhakumar R, Dewey W, Kelly E, Henderson G. Fentanyl depression of respiration: comparison with heroin and morphine. Br J Pharmacol 2020;177:254-265.
47. Manzke T, Guenther U, Ponimaskin EG, Haller M, Dutschmann M, Schwarzacher S, Richter DW. 5-HT4(a) receptors avert opioid-induced breathing depression without loss of analgesia. Science 2003;301:226-229.
48. Nisbet AT, Mooney-Cotter F. Comparison of selected sedation scales for reporting opioid-induced sedation assessment. Pain Manag Nurs 2009;10:154-164.
49. Roeckel LA, Le Coz GM, Gaveriaux-Ruff C, Simonin F. Opioid-induced hyperalgesia: Cellular and molecular mechanisms. Neuroscience 2016;338:160-182.
50. Liu XY, Liu ZC, Sun YG, Ross M, Kim S, Tsai FF, Li QF, Jeffry J, Kim JY, Loh HH, Chen ZF. Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids. Cell 2011;147:447-458.